Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Alexza Pharmaceuticals, Inc. |
---|---|
Information provided by: | Alexza Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00444522 |
We are developing Staccato Alprazolam for the acute treatment of panic attacks associated with panic disorder.
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: Alprazolam thermal aerosol |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Safety, Tolerability, and Pharmacokinetics of a Single Dose of StaccatoTM Alprazolam for Inhalation in Normal, Healthy Volunteers |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | AMDC-002-101 |
Study First Received: | March 5, 2007 |
Last Updated: | March 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00444522 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Panic attacks, Staccato® Alprazolam |
Neurotransmitter Agents Panic Disorder Tranquilizing Agents Alprazolam Hypnotics and Sedatives |
Psychotropic Drugs Central Nervous System Depressants Anti-Anxiety Agents Healthy |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action GABA Modulators Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants |
Pharmacologic Actions Alprazolam Therapeutic Uses Hypnotics and Sedatives GABA Agents Anti-Anxiety Agents Central Nervous System Agents |